Skip to content
The People's CodeSearch
Menu

Changes to the Code

H.R. 5197 · Protect Beneficiaries from Middlemen Act ·

In committee · step 2 of 5

Sections are cited like “7 U.S.C. § 2012”: 7 of the , 2012.

42 U.S.C. § 1395w–102 Prescription drug benefits

+13 −2Shown
More for 42 U.S.C. § 1395w–102
Read § 1395w–102Only this section
4 changes the bill asks for here, 4 carried out
  1. Carried out:

    in paragraph (2)(A), by striking (8) and (9) and inserting (8), (9), and (10);

  2. Carried out:

    in paragraph (9)(B)(ii), by striking For a plan year and inserting Subject to paragraph (10), for a plan year; and

  3. Carried out:

    by adding at the end the following new paragraph:(10) Limitation on cost sharing to net price amount.— (A) In general.— For a plan year beginning on or after January 1, 2027, the coverage provides benefits for a supply of a covered part D drug dispensed by a pharmacy, for costs in excess of the deductible specified in …

  4. Carried out:

    in subsection (c), by adding at the end the following new paragraph:(7) Cost sharing limited to net price.— The coverage is provided in accordance with subsection (b)(10)..

§ 1395w–102(b)Standard prescription drug coverage(1)–(2)

Start of § 1395w–102 to (b)(1)(A)(ii) unchanged ·

(B) Rounding Any amount determined under subparagraph (A)(ii) that is not a multiple of $5 shall be rounded to the nearest multiple of $5.

(2) Benefit structure

(A) 25 percent coinsurance Subject to subparagraphs (C), (D), and (E) and paragraphs (8)[inserted: ,] [inserted: (9), ]and ([struck: 9][inserted: 10]), the coverage has coinsurance (for costs above the annual deductible specified in paragraph (1) and up to the initial coverage limit under paragraph (3) for a year preceding 2025 and for costs above the annual deductible specified in paragraph (1) and up to the annual out-of-pocket threshold specified in paragraph (4)(B) for 2025 and each subsequent year) that is—

(i) equal to 25 percent; or

(ii) actuarially equivalent (using processes and methods established under section 1395w–111(c) of this title) to an average expected payment of 25 percent of such costs.

§ 1395w–102(b)(9)Treatment of cost-sharing for covered insulin products(B)–(D)

(b)(2)(B)–(9)(B) unchanged ·

(i) Plan years 2023 and 2024 For plan years 2023 and 2024, the coverage provides benefits for any covered insulin product, regardless of whether an individual has reached the initial coverage limit under paragraph (3) or the out-of-pocket threshold under paragraph (4), with cost-sharing for a month’s supply that does not exceed the applicable copayment amount.

(ii) Plan year 2025 and subsequent plan years [struck: For][inserted: Subject] [inserted: to paragraph (10), for ]a plan year beginning on or after January 1, 2025, the coverage provides benefits for any covered insulin product, prior to an individual reaching the out-of-pocket threshold under paragraph (4), with cost-sharing for a month’s supply that does not exceed the applicable copayment amount.

(C) Covered insulin product In this paragraph, the term “covered insulin product” means an insulin product that is a covered part D drug covered under the prescription drug plan or MA–PD plan that is approved under section 355 of title 21 or licensed under section 351 of the Public Health Service Act [42 U.S.C. 262] and marketed pursuant to such approval or licensure, including any covered insulin product that has been deemed to be licensed under section 351 of the Public Health Service Act pursuant to section 7002(e)(4) of the Biologics Price Competition and Innovation Act of 2009 and marketed pursuant to such section.

(D) Applicable copayment amount In this paragraph, the term “applicable copayment amount” means, with respect to a covered insulin product under a prescription drug plan or an MA–PD plan dispensed—

§ 1395w–102(b)–(c)

(b)(9)(D)(i)–(ii) unchanged ·

(III) an amount equal to 25 percent of the negotiated price of the covered insulin product under the prescription drug plan or MA–PD plan.

(E) Special rule for first 3 months of 2023 With respect to a month’s supply of a covered insulin product dispensed during the period beginning on January 1, 2023, and ending on March 31, 2023, a PDP sponsor offering a prescription drug plan or an MA organization offering an MA–PD plan shall reimburse an enrollee within 30 days for any cost-sharing paid by such enrollee that exceeds the cost-sharing applied by the prescription drug plan or MA–PD plan under subparagraph (B)(i) at the point-of-sale for such month’s supply.

(10) [inserted: Limitation on cost sharing to net price amount.—]

(A) [inserted: In general.—] [inserted: For a plan year beginning on or after January 1, 2027, the coverage provides benefits for a supply of a covered part D drug dispensed by a pharmacy, for costs in excess of the deductible specified in paragraph (1) and prior to an individual reaching the out-of-pocket threshold under paragraph (4), with cost-sharing for a month’s supply that does not exceed the average net price for such a supply of such drug during such plan year (or, if lower, the applicable cash price for such a supply of such drug so dispensed by such pharmacy).]

(B) [inserted: Definitions.—] [inserted: In this paragraph:]

(i) [inserted: Applicable cash price.—] [inserted: The term “applicable cash price” means, with respect to a supply of a covered part D drug dispensed by a pharmacy, the price that such pharmacy would charge for such supply of such drug dispensed to an individual without benefits for such drug under any Federal health care program (as defined in section 1128B), a group health plan or group or individual health insurance coverage (as such terms are defined in section 2791 of the Public Health Service Act), or the program established under chapter 89 of title 5, United States Code.]

(ii) [inserted: Average net price.—] [inserted: The term “average net price” means, with respect to a supply of a covered part D drug, a prescription drug plan, and a plan year, the average amount paid under such plan (including any amounts paid by an individual enrolled under such plan as cost sharing for such drug) as payment for such a supply of such drug dispensed during such year, less any rebates or other forms of remuneration received under such plan with respect to such drug.]

(c) Alternative prescription drug coverage requirements A prescription drug plan or an MA–PD plan may provide a different prescription drug benefit design from standard prescription drug coverage so long as the Secretary determines (consistent with section 1395w–111(c) of this title) that the following requirements are met and the plan applies for, and receives, the approval of the Secretary for such benefit design:

(1) Assuring at least actuarially equivalent coverage

§ 1395w–102(c)–(d)

(c)(1)(A)–(4) unchanged ·

(5) Treatment of cost-sharing for adult vaccines recommended by the Advisory Committee on Immunization Practices The coverage is in accordance with subsection (b)(8).

(6) Treatment of cost-sharing for covered insulin products The coverage is provided in accordance with subsection (b)(9).

(7) [inserted: Cost sharing limited to net price.—] [inserted: The coverage is provided in accordance with subsection (b)(10).]

(d) Access to negotiated prices

(1) Access

(A) In general Under qualified prescription drug coverage offered by a PDP sponsor offering a prescription drug plan or an MA organization offering an MA–PD plan, the sponsor or organization shall provide enrollees with access to negotiated prices used for payment for covered part D drugs, regardless of the fact that no benefits may be payable under the coverage with respect to such drugs because of the application of a deductible or other cost-sharing or, for a year preceding 2025, an initial coverage limit (described in subsection (b)(3)).

Rest of § 1395w–102 unchanged ·

42 U.S.C. § 1395w–114 Premium and cost-sharing subsidies for low-income individuals

+1 −1Shown
More for 42 U.S.C. § 1395w–114
Read § 1395w–114Only this section
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Section 1860D–14(a)(1)(D)(iii) of the Social Security Act (42 U.S.C. 1395w–114(a)(1)(D)(iii)) is amended by adding at the end the following new sentence: For plan year 2027 and subsequent plan years, the copayment amount applicable under this clause to a supply of a covered part D drug dispensed to the individual may not exceed the amount provided under section 1860D–2(b)(10)..

§ 1395w–114(a)Income-related subsidies for certain individuals(1)–(2)

Start of § 1395w–114 to (a)(1)(D)(ii)(II)(bb) unchanged ·

(cc) for a drug not described in either item (aa) or (bb), the dollar amount applied under this clause for such a drug for the preceding plan year, increased in the manner specified in item (bb), or, if less, the copayment amount applicable to an individual under clause (iii).

Any amount established under item (bb) or (cc) of subclause (II), that is based on an increase of $1 or $3, that is not a multiple of 5 cents or 10 cents, respectively, shall be rounded to the nearest multiple of 5 cents or 10 cents, respectively.

(iii) Other individuals Subject to paragraph (6), in the case of an individual not described in clause (i) or (ii), the substitution for the beneficiary coinsurance described in section 1395w–102(b)(2) of this title (for all amounts through the total amount of expenditures at which benefits are available under section 1395w–102(b)(4) of this title) of a copayment amount that does not exceed the copayment amount specified under section 1395w–102(b)(4)(A)(i)(I)(aa) of this title for the drug and year involved. For plan year 2023 and subsequent plan years, the copayment amount applicable under the preceding sentence to a month’s supply of a covered insulin product (as defined in section 1395w–102(b)(9)(C) of this title) dispensed to the individual may not exceed the applicable copayment amount for the product under the prescription drug plan or MA–PD plan in which the individual is enrolled.[inserted: For plan year 2027 and subsequent plan years, the copayment amount applicable under this clause to a supply of a covered part D drug dispensed to the individual may not exceed the amount provided under section 1860D–2(b)(10).]

(E) Elimination of cost-sharing above annual out-of-pocket threshold For a year preceding 2024, the elimination of any cost-sharing imposed under section 1395w–102(b)(4)(A) of this title or under section 1395w–102(b)(9) of this title in the case of a covered insulin product (as defined in subparagraph (C) of such section).

(2) Other low-income individuals With respect to a plan year beginning before January 1, 2024, in the case of a subsidy eligible individual who is not described in paragraph (1), the individual is entitled under this section to the following:

Rest of § 1395w–114 unchanged ·

Step through the changes